Insight Molecular Diagnostics Inc. — Director's Dealing 2019

Mar 18, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: OncoCyte Corp (OCX)
CIK: 0001642380
Period of Report: 2019-03-14

Reporting Person: Levine Mitchell S (Chief Financial Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-03-14	Option to Purchase Common Stock	$3.52	A	245000	Acquired	2019-03-13	Common Stock (245000)	Direct
2019-03-14	Restricted Stock Units	$	A	20000	Acquired		Common Stock (20000)	Direct

Footnotes

F1: One quarter of the options shall vest upon the completion of one year of continuous service from the date of grant on March 14, 2019 and the balance shall vest in 36 equal monthly installments commencing on the first anniversary of the date of grant, based on continuous service on the applicable vesting date.

F2: Grant of restricted stock units under the OncoCye 2018 Equity Incentive Plan. Each restricted stock unit represents a contingent right to receive one share of Common Stock.

F3: The restricted stock units shall vest upon the completion of one year of continuous service from the date of grant.